A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma:a meta-analysis
Backgrounds: Glypican-3(GPC-3) has been reported as one of the most promising serum markers for hepatocellular carcinoma (HCC), while several studies have conflicting results for the diagnostic accuracy between GPC-3 and alpha-fetoprotein (AFP).Methods : Studies that explored the diagnostic value of GPC-3 and AFP in HCC were searched in MEDLINE, EMBASE, PUBMED, the Cochrane Library and Chinese BioMedical Literature Database (CBM).Sensitivity, specificity and other measures about the accuracy of serum GPC-3 and AFP in the diagnosis of HCC were pooled using random-effects models.Summary receiver operating characteristic curve (sROC) analysis was used to summarize the overall test performance.Resu l ts : Ten studies were included in our meta-analysis.The pooled sensitivity for AFP and GPC-3 are: AFP 51.9% (95%confidence interval (CI): 0.47-0.56), GPC-3 59.2% (95%CI:0.55-0.63); while the pooled specificity for AFP and GPC-3 are: AFP 94% (95%CI:92.1% to 95.6%), GPC-3 84.8% (95%CI:82% to 87.3%).The pooled diagnostic odds ratio (DOR): AFP 23.4 (95%CI: 10.3-53.2), GPC-3 17.99 (95%CI:5.4-60.4).Area under sROC for AFP and GPC-3 are the same as 0.81 (95%CI: 0.77-0.84).Conclusions: GPC-3 is comparable to AFP as a serum marker for the diagnosis of HCC, combination of AFP and GPC-3 can elevate the sensitivity of diagnosis.
AFP GPC-3 diagnostic accuracy hepatocellular carcinoma
Cheng Xu Zhehui Yan Liang Zhou Yuming Wang
Institute of Infectious Diseases, Southwest Hospital, the Third Military Medical University, Chongqing 400038, P.R.China
国内会议
重庆
英文
232-240
2013-08-29（万方平台首次上网日期，不代表论文的发表时间）